NCT03412877 2026-04-20
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
190 trialsNCT03485209 2026-04-20
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT04638582 2026-04-17
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Terminated
NCT03634241 2026-04-16
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT04225117 2026-04-13
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT07221474 2026-04-13
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04317534 2026-04-08
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05077709 2026-04-08
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
Phase 2 Completed
NCT06099782 2026-04-08
MK-3475A-F11
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06745882 2026-04-02
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07353957 2026-04-02
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Merus B.V.
Phase 2 Recruiting
NCT06788912 2026-03-31
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04736173 2026-03-30
ARC-10
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT06008093 2026-03-30
TRITON
AstraZeneca
Phase 2 Active not recruiting
NCT03463460 2026-03-23
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05669846 2026-03-23
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
University of Pittsburgh
Phase 2 Recruiting
NCT07486817 2026-03-23
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
Phase 2 Not yet recruiting
NCT04253964 2026-03-19
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT07452224 2026-03-12
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
iLeukon Therapeutics, Inc.
Phase 2 Not yet recruiting
NCT07017829 2026-03-11
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT07264816 2026-03-05
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07098988 2026-02-27
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT04710628 2026-02-19
PECATI
MedSIR
Phase 2 Completed
NCT06731907 2026-02-18
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06731270 2026-02-12
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
Phase 2 Recruiting
NCT05186974 2026-02-11
EVOKE-02
Gilead Sciences
Phase 2 Active not recruiting
NCT05775289 2026-02-11
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07360743 2026-02-10
META-1
UNICANCER
Phase 2 Not yet recruiting
NCT04340882 2026-01-30
DoceRamPem
Emory University
Phase 2 Active not recruiting
NCT05816252 2026-01-27
MK-2870-003
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT04166487 2026-01-21
Plasma-Adapted First-Line Pembro In NSCLC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06155279 2026-01-13
CHIMERA
Istituto Oncologico Veneto IRCCS
Phase 2 Active not recruiting
NCT05565378 2026-01-08
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05613413 2026-01-08
LUNG-IST-127
University of Illinois at Chicago
Phase 2 Recruiting
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT05570825 2025-12-04
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
University of Washington
Phase 2 Recruiting
NCT04165083 2025-11-26
MK-3475-01B
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03137771 2025-11-25
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Active not recruiting
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT02316002 2025-11-06
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT05117242 2025-11-06
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
Genmab
Phase 2 Active not recruiting
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT04524689 2025-10-29
CARMEN-LC05
Sanofi
Phase 2 Terminated
NCT06558799 2025-10-28
LUNAR-4
NovoCure Ltd.
Phase 2 Active not recruiting
NCT03049618 2025-10-22
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
Phase 2 Completed